Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Amgen, Baxter Eye Biosimilars

by Michael McCoy
January 2, 2012 | A version of this story appeared in Volume 90, Issue 1

Two big drug companies have formed ventures aimed at developing generic, or biosimilar, versions of biologic drugs. Amgen and Watson Pharmaceuticals are joining to develop biosimilars of oncology antibodies other than ones already made by Amgen, the world’s largest biotech firm. Amgen will be responsible for developing, manufacturing, and commercializing the drugs. Watson will contribute up to $400 million and its generic drug development and marketing know-how. Baxter International and Momenta Pharmaceuticals, meanwhile, have formed a pact to develop up to six biosimilars. Momenta brings the experience of having won FDA approval last year for a biosimilar version of Lovenox, a low-molecular-weight heparin marketed by Sanofi. Momenta will get $33 million up front from Baxter and is eligible to receive milestone payments of more than $470 million. Biogen Idec, another big drug company, formed a biosimilars venture with Samsung last month.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.